Physician profile
Sarah E Holy
NPI 1275514796
$17,767.07
in general payments reported to CMS, 2019-2025
25 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,955 · 2020: $713 · 2021: $2,494 · 2022: $9,880 · 2023: $1,533 · 2024: $555 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $11,635.02 | 2019-2022 | |
| Alimera Sciences, INC. | $1,169.37 | 2019-2024 | Yutiq, Iluvien |
| Genentech USA, INC. | $990.63 | 2019-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $698.36 | 2021-2025 | Centurion, Clareon, Constellation |
| Allergan, INC. | $335.88 | 2019-2021 | |
| Biotissue Holdings INC. | $299.85 | 2023-2024 | |
| Regeneron Pharmaceuticals, INC. | $280.07 | 2021-2024 | Eylea, Eylea Hd |
| Notal Vision, INC. | $268.25 | 2022 | |
| Apellis Pharmaceuticals, INC. | $255.67 | 2022-2023 | Syfovre |
| Astellas Pharma US INC | $246.03 | 2023 | Izervay |
| Novartis Pharmaceuticals Corporation | $203.95 | 2019 | |
| Eyepoint US, INC. | $173.40 | 2020-2022 | |
| Biogen, INC. | $154.43 | 2022-2023 | |
| Ocular Therapeutix, INC. | $146.38 | 2021-2024 | Dextenza |
| Amgen INC. | $121.86 | 2025 | Uplizna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $120.14 | 2019 | |
| Ani Pharmaceuticals, INC. | $111.66 | 2025 | Yutiq |
| Regeneron Healthcare Solutions, INC. | $102.60 | 2023 | Eylea Hd |
| Rxsight INC | $101.10 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $98.24 | 2020 | |
| Novo Nordisk INC | $82.17 | 2021 | |
| Coherus Oncology, INC. | $26.10 | 2023 | |
| Bausch & Lomb Americas INC. | $23.33 | 2023 | Visudyne, Xipere |
| Abbvie INC. | $22.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Holy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.